Search results for "COVID-19( vaccin)"

showing 10 items of 65 documents

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

2021

AbstractThere is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that tumor and treatment-related immunosuppression can be depicted in peripheral blood, and that immune profiling prior to vaccination can help predict immunogenicity. We performed a comprehensive immunological characterization of 83 hematological patients before vaccination and measured IgM, IgG, and IgA antibody response to four viral antigens at day +7 after second-dose COVID-19 vaccination using multidimensional and computational flow cytometry. Health care practitioners of similar age were the control group (n = 102). Forty-four out of 59 immune cell types …

AdultAged 80 and overMaleHaematological cancerCOVID-19 VaccinesSARS-CoV-2COVID-19Vaccine EfficacyNeoplasms. Tumors. Oncology. Including cancer and carcinogenslymphomaHematologyMiddle Agedhematologic malignancieArticleImmunocompromised HostmyelomaOncologyHematologic NeoplasmsHumansTumour immunologyFemaleSars-cov-BiomarkersRC254-282AgedBlood Cancer Journal
researchProduct

Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy.

2021

Background: Previous research has shown that young adults are more hesitant/resistant to COVID-19 vaccine uptake than older age groups, although the factors underlying this tendency are still under debate. The current study aimed to identify the sociodemographic and psychological correlates of vaccine hesitancy and resistance among young adults (18–40 years) during the nationwide COVID-19 vaccination campaign in Italy, the first country after China being hit by the pandemic and which suffered a large number of fatalities. Methods: This is a cross-sectional, web-based study conducted in Italy using an ISO-certified international survey company (respondi.com). Data were collected on 1200 part…

AdultCOVID-19 VaccinesGeneral VeterinaryGeneral Immunology and MicrobiologySARS-CoV-2VaccinationPublic Health Environmental and Occupational HealthCOVID-19; Italy; Psychological correlates; Vaccine hesitancy; Young adults; Adult; Aged; Cross-Sectional Studies; Humans; SARS-CoV-2; Vaccination; Vaccination Hesitancy; Young Adult; COVID-19; COVID-19 VaccinesCOVID-19Settore M-PSI/04 - Psicologia Dello Sviluppo E Psicologia Dell'EducazioneYoung AdultInfectious DiseasesCross-Sectional StudiesItalyMolecular MedicinePsychological correlatesHumansVaccination HesitancySettore M-PSI/05 - Psicologia SocialeVaccine hesitancyYoung adultsAgedVaccine
researchProduct

Exploring the effectiveness of the Digital Green Certificate Law as Public Health instrument to increase anti-COVID-19 vaccination in a sample of wor…

2022

Counteracting vaccine hesitancy should be considered an absolute priority for Public Health Authorities. A correct health communication represents one of the best ways to increase adhesion to vaccination among hesitant population. In order to increase vaccination coverage rates against COVID-19, the Italian government has issued a legislative decree with a mandatory “Digital Green Certificate” (DGC) to access workplaces for some categories considered at risk. Methods. We conducted a cross-sectional study with the aim to highlight the factors associated with the anti-COVID-19 vaccine acceptance and to estimate the influence of the introduction by law of the Digital Green Certificate (DGC) on…

AdultCross-Sectional StudiesCOVID-19 VaccinesCOVID-19 vaccinationMandatory vaccination.VaccinationHumansCOVID-19Public HealthDigital Green CertificateGreen Pass LawJournal of preventive medicine and hygiene
researchProduct

Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study

2022

Breast milk is a vehicle to transfer protective antibodies from the lactating mother to the neonate. After SARS-CoV-2 infection, virus-specific IgA and IgG have been identified in breast milk, however, there are limited data on the impact of different COVID-19 vaccine types in lactating women. This study is aimed to evaluate the time course of induction of SARS-CoV-2-specific IgA and IgG in breast milk after vaccination.

AdultLongitudinal studyBreast milkCOVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BreastfeedingimmunoglobulinsImmunoglobulinsBreast milkAntibodies ViralVacunesAntibodiesVirusPersistence (computer science)ChAdOx1 nCoV-19GeneticsHumansLactationMedicineantibodiesLongitudinal Studiesskin and connective tissue diseasesMolecular BiologyBNT162 VaccineGenetics (clinical)Milk Humanbiologybusiness.industrySARS-CoV-2VaccinationInfant Newbornfood and beveragesInfantCOVID-19vaccinesImmunoglobulin AVaccinationLlet maternaImmunoglobulin GImmunologybiology.proteinMolecular Medicinebreast milkFemaleAntibodybusiness
researchProduct

B and T cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing home residents

2021

Objectives The immunogenicity of the Comirnaty® COVID-19 vaccine is understudied in elderly people with comorbidities. SARS-CoV-2-S-targeted antibody and T cell responses following full vaccination were assessed in nursing home residents. Methods Sixty nursing home residents (44 female; age, 53-100 years), of whom 10 had previously been diagnosed of COVID-19, and 18 healthy controls (15 female; age, 27-54 years) were recruited. Pre- and post-vaccination blood specimens were available for quantitation of total antibodies binding SARS-CoV-2 S protein and enumeration of SARS-CoV-2-S-reactive IFN-γ CD4+ and CD8+ T cells by flow cytometry. Results The seroconversion rate in presumably SARS-CoV-2…

AdultMale0301 basic medicineMicrobiology (medical)COVID-19 VaccinesSARS-CoV-2-S antibodiesT-LymphocytesT cell030106 microbiologyNursing home residentsAntibodies ViralFlow cytometryInterferon-gamma03 medical and health sciences0302 clinical medicineImmune systemComirnaty®COVID-19 vaccinemedicineHumans030212 general & internal medicineSeroconversionAgedAged 80 and overB-Lymphocytesbiologymedicine.diagnostic_testbusiness.industrySARS-CoV-2ImmunogenicityImmunityCOVID-19General MedicineMiddle AgedNursing HomesVaccinationInfectious Diseasesmedicine.anatomical_structureSARS-CoV-2-S T cellsSpike Glycoprotein CoronavirusImmunologybiology.proteinFemaleOriginal ArticleAntibodybusinessCD8Clinical Microbiology and Infection
researchProduct

Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy

2021

Therapies - Sous presse. Epreuves corrigees par l'auteur. Disponible en ligne depuis le mardi 13 avril 2021

AdultMale2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19 vaccines030226 pharmacology & pharmacyArticle03 medical and health sciencesPharmacovigilance0302 clinical medicineBell's palsyPhase 3 clinical trialsBell PalsymedicineType I interferonsHumansBell's palsyPharmacology (medical)Potential mechanismComputingMilieux_MISCELLANEOUSAgedCOVID-19 coronavirus disease 2019Vaccines SyntheticMessenger RNASARS-CoV-2business.industryCOVID-19Bell’s palsyMiddle Agedmedicine.diseaseVirologymRNA messenger RNA3. Good healthInterferon Type IFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct

Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents.

2022

Immunosenescence may impact the functionality and breadth of vaccine-elicited humoral immune responses. The ability of sera to neutralize the SARS-CoV-2 spike protein (S) from Beta, Gamma, Delta, and Epsilon variants of concern (VOCs) relative to the ancestral Wuhan-Hu-1 strain was compared in Comirnaty COVID-19-vaccinated elderly nursing home residents, either SARS-CoV-2 naïve (n = 22) or experienced (n = 8), or SARS-CoV-2 naïve younger individuals (n = 18) and non-vaccinated individuals who recovered from severe COVID-19 (n = 19). In all groups, except that including SARS-CoV-2-experienced nursing home residents, some participants lacked NtAb against one or more VOCs, mainly the Beta vari…

AdultMaleCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibodies ViralImmune systemProtein DomainsNeutralization TestsMedicineHumansBeta (finance)AgedRetrospective StudiesAged 80 and overMultidisciplinarybiologybusiness.industrySARS-CoV-2COVID-19ImmunosenescenceMiddle AgedAntibodies NeutralizingFold changeImmunity HumoralNursing HomesTiterImmunologySpike Glycoprotein Coronavirusbiology.proteinFemaleAntibodybusinessScientific reports
researchProduct

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

2021

Vaccine protects against B1.1.7 variant The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1.7 might compromise the effectiveness of the vaccine. Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein (see the Perspective by Altmann et al.). Serum was derived from 40 subjects in tw…

AdultMaleChinaCOVID-19 VaccinesLineage (genetic)Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibodies ViralNeutralizationYoung AdultNeutralization TestsReportHumansBNT162 VaccineAgedchemistry.chemical_classificationVaccinesMessenger RNAMultidisciplinarybiologySARS-CoV-2COVID-19MicrobioMiddle AgedAntibodies NeutralizingVirologyUnited KingdomAmino acidTiterchemistrySpike Glycoprotein Coronavirusbiology.proteinMedicineFemaleAntibodyReportsScience
researchProduct

The Vaccination Concerns in COVID-19 Scale (VaCCS) : Development and validation

2022

Vaccines are highly effective in minimizing serious cases of COVID-19 and pivotal to managing the COVID-19 pandemic. Despite widespread availability, vaccination rates fall short of levels required to bring about widespread immunity, with low rates attributed to vaccine hesitancy. It is therefore important to identify the beliefs and concerns associated with vaccine intentions and uptake. The present study aimed to develop and validate, using the AMEE Guide, the Vaccination Concerns in COVID-19 Scale (VaCCS), a comprehensive measure of beliefs and concerns with respect to COVID-19 vaccines. In the scale development phase, samples of Australian (N = 53) and USA (N = 48) residents completed a…

AdultMaleand promotion of well-beingCOVID-19 VaccinesAdolescentGeneral Science & TechnologyVaccine RelatedYoung AdultClinical ResearchBehavioral and Social ScienceHumansterveyskäsityksetPreventionrokotteetAustraliaCOVID-19StatisticalMiddle AgedPrevention of disease and conditionsUnited StatesGood Health and Well Being3.4 VaccinesterveyskäyttäytyminenFemaleImmunizationVaccination HesitancyInfectionFactor AnalysisMind and Bodyrokotevastaisuus
researchProduct

Reply to “Caution in underrepresentation of older adults in clinical trials on COVID-19 vaccines”

2021

We would like to thank Chen et al. for their comments on our recently published paper in Ageing Research Reviews (Veronese et al., 2021). In this reply we would like to answer to the points raised in their letter. Regarding the first question, we decided to run our search only in PubMed/Medline and ClinicalTrials.gov since the phase II-III randomized controlled trials of SARS-CoV 2 vaccines, considering the urgency for interventions to ameliorate the pandemic situation, received a great deal of interest. Therefore, they were usually published in high impact factor journals, reported in PubMed, and their protocols were usually reported in clinicaltrials.gov. However, following the suggestion…

Agingmedicine.medical_specialtyCOVID-19 Vaccinesmedia_common.quotation_subjectMEDLINEPsychological interventionBiochemistryArticlelaw.inventionRandomized controlled triallawAged Humans SARS-CoV-2 COVID-19 COVID-19 VaccinesmedicineHumansQuality (business)Molecular Biologymedia_commonAgedProtocol (science)Vaccinesbusiness.industrySARS-CoV-2COVID-19Clinical trialNeurologyPublishingFamily medicineParagraphbusinessPsychologyBiotechnologyAged; Humans; SARS-CoV-2; COVID-19; COVID-19 Vaccines
researchProduct